vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and IMMERSION CORP (IMMR). Click either name above to swap in a different company.

IMMERSION CORP is the larger business by last-quarter revenue ($372.9M vs $196.0M, roughly 1.9× Axsome Therapeutics, Inc.). IMMERSION CORP runs the higher net margin — -4.6% vs -14.6%, a 10.0% gap on every dollar of revenue. On growth, IMMERSION CORP posted the faster year-over-year revenue change (750.4% vs 65.0%). Over the past eight quarters, IMMERSION CORP's revenue compounded faster (537.9% CAGR vs 61.7%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Immersion Corporation is an Aventura, Florida based developer and licensor of touch feedback technology, also known as haptic technology. Immersion Corporation has been accused of being a patent troll. Founded in 1993 by Louis Rosenberg, it is currently headed by lawyer Francis Jose, who serves as both chief executive officer and general counsel.

AXSM vs IMMR — Head-to-Head

Bigger by revenue
IMMR
IMMR
1.9× larger
IMMR
$372.9M
$196.0M
AXSM
Growing faster (revenue YoY)
IMMR
IMMR
+685.4% gap
IMMR
750.4%
65.0%
AXSM
Higher net margin
IMMR
IMMR
10.0% more per $
IMMR
-4.6%
-14.6%
AXSM
Faster 2-yr revenue CAGR
IMMR
IMMR
Annualised
IMMR
537.9%
61.7%
AXSM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
IMMR
IMMR
Revenue
$196.0M
$372.9M
Net Profit
$-28.6M
$-17.0M
Gross Margin
Operating Margin
-13.8%
-2.8%
Net Margin
-14.6%
-4.6%
Revenue YoY
65.0%
750.4%
Net Profit YoY
61.9%
-191.3%
EPS (diluted)
$-0.55
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
IMMR
IMMR
Q4 25
$196.0M
Q3 25
$171.0M
Q2 25
$150.0M
$372.9M
Q1 25
$121.5M
$471.3M
Q4 24
$118.8M
$616.2M
Q3 24
$104.8M
Q2 24
$87.2M
$95.5M
Q1 24
$75.0M
$43.8M
Net Profit
AXSM
AXSM
IMMR
IMMR
Q4 25
$-28.6M
Q3 25
$-47.2M
Q2 25
$-48.0M
$-17.0M
Q1 25
$-59.4M
$24.1M
Q4 24
$-74.9M
$30.8M
Q3 24
$-64.6M
Q2 24
$-79.3M
$26.4M
Q1 24
$-68.4M
$18.7M
Operating Margin
AXSM
AXSM
IMMR
IMMR
Q4 25
-13.8%
Q3 25
-27.0%
Q2 25
-24.5%
-2.8%
Q1 25
-46.9%
7.5%
Q4 24
-61.1%
11.4%
Q3 24
-59.8%
Q2 24
-89.5%
23.7%
Q1 24
-89.7%
37.9%
Net Margin
AXSM
AXSM
IMMR
IMMR
Q4 25
-14.6%
Q3 25
-27.6%
Q2 25
-32.0%
-4.6%
Q1 25
-48.9%
5.1%
Q4 24
-63.1%
5.0%
Q3 24
-61.7%
Q2 24
-91.0%
27.7%
Q1 24
-91.1%
42.5%
EPS (diluted)
AXSM
AXSM
IMMR
IMMR
Q4 25
$-0.55
Q3 25
$-0.94
Q2 25
$-0.97
$-0.57
Q1 25
$-1.22
$0.73
Q4 24
$-1.54
$0.93
Q3 24
$-1.34
Q2 24
$-1.67
$0.81
Q1 24
$-1.44
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
IMMR
IMMR
Cash + ST InvestmentsLiquidity on hand
$322.9M
$161.4M
Total DebtLower is stronger
$103.1M
Stockholders' EquityBook value
$88.3M
$298.1M
Total Assets
$689.8M
$1.1B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
IMMR
IMMR
Q4 25
$322.9M
Q3 25
$325.3M
Q2 25
$303.0M
$161.4M
Q1 25
$300.9M
$153.9M
Q4 24
$315.4M
$159.3M
Q3 24
$327.3M
Q2 24
$315.7M
$133.4M
Q1 24
$331.4M
$179.1M
Total Debt
AXSM
AXSM
IMMR
IMMR
Q4 25
Q3 25
Q2 25
$103.1M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AXSM
AXSM
IMMR
IMMR
Q4 25
$88.3M
Q3 25
$73.7M
Q2 25
$73.1M
$298.1M
Q1 25
$53.2M
$317.9M
Q4 24
$57.0M
$305.5M
Q3 24
$92.9M
Q2 24
$102.9M
$273.4M
Q1 24
$144.0M
$201.5M
Total Assets
AXSM
AXSM
IMMR
IMMR
Q4 25
$689.8M
Q3 25
$669.3M
Q2 25
$639.8M
$1.1B
Q1 25
$596.7M
$1.4B
Q4 24
$568.5M
$1.4B
Q3 24
$561.5M
Q2 24
$548.2M
$1.2B
Q1 24
$545.7M
$244.7M
Debt / Equity
AXSM
AXSM
IMMR
IMMR
Q4 25
Q3 25
Q2 25
0.35×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
IMMR
IMMR
Operating Cash FlowLast quarter
$-18.7M
Free Cash FlowOCF − Capex
$-18.7M
FCF MarginFCF / Revenue
-9.6%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
IMMR
IMMR
Q4 25
$-18.7M
Q3 25
$1.0M
Q2 25
$-32.4M
Q1 25
$-43.4M
$-43.7M
Q4 24
$-26.2M
Q3 24
$-18.6M
Q2 24
$-30.1M
$-85.9M
Q1 24
$-53.5M
$29.9M
Free Cash Flow
AXSM
AXSM
IMMR
IMMR
Q4 25
$-18.7M
Q3 25
$988.0K
Q2 25
$-32.4M
Q1 25
$-43.7M
$-46.2M
Q4 24
$-26.2M
Q3 24
$-18.7M
Q2 24
$-30.2M
Q1 24
$-53.6M
FCF Margin
AXSM
AXSM
IMMR
IMMR
Q4 25
-9.6%
Q3 25
0.6%
Q2 25
-21.6%
Q1 25
-36.0%
-9.8%
Q4 24
-22.1%
Q3 24
-17.9%
Q2 24
-34.6%
Q1 24
-71.4%
Capex Intensity
AXSM
AXSM
IMMR
IMMR
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.3%
0.5%
Q4 24
0.0%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
AXSM
AXSM
IMMR
IMMR
Q4 25
Q3 25
Q2 25
Q1 25
-1.82×
Q4 24
Q3 24
Q2 24
-3.25×
Q1 24
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

IMMR
IMMR

Course Material Sale$150.9M40%
General Merchandise Sale$138.0M37%
Rental Services$51.8M14%
Services And Other Revenue$25.6M7%
Per Unit Royalties$1.8M0%

Related Comparisons